In the present study, we analysed the association between the CCR5 Δ32 and CTLA-4 +49 A/G gene polymorphisms and the clinical response to IFN-β treatment in Croatian and Slovenian MS patients. This evidence concerns the gene CCR5 and myeloid sarcoma.